PolyPid & ImmunoGenesis Partner for Cancer Immunotherapy
Ticker: PYPD · Form: 6-K · Filed: Dec 11, 2024 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, R&D, cancer-immunotherapy, biotech
TL;DR
PolyPid teams up with ImmunoGenesis to boost cancer immunotherapy using PLEX tech.
AI Summary
PolyPid Ltd. announced on December 11, 2024, a research and development collaboration with ImmunoGenesis. This partnership will leverage PolyPid's PLEX technology to enhance cancer immunotherapy. The collaboration aims to develop novel therapeutic approaches for cancer treatment.
Why It Matters
This collaboration could lead to new and improved cancer treatments by combining PolyPid's innovative drug delivery technology with ImmunoGenesis's expertise in immunotherapy.
Risk Assessment
Risk Level: medium — Collaborations in R&D carry inherent risks related to development timelines, efficacy, and market adoption.
Key Players & Entities
- PolyPid Ltd. (company) — Announcing company
- ImmunoGenesis (company) — Collaboration partner
- PLEX Technology (technology) — Technology being leveraged
- December 11, 2024 (date) — Date of announcement
FAQ
What is the primary goal of the collaboration between PolyPid and ImmunoGenesis?
The primary goal is to leverage PolyPid's PLEX technology to enhance cancer immunotherapy.
What specific technology is PolyPid contributing to the collaboration?
PolyPid is contributing its PLEX technology.
What area of medicine is the collaboration focused on?
The collaboration is focused on cancer immunotherapy.
When was this collaboration announced?
The collaboration was announced on December 11, 2024.
What type of issuer is PolyPid Ltd. filing as?
PolyPid Ltd. is filing as a Foreign Private Issuer.
Filing Stats: 299 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-12-11 07:05:07
Filing Documents
- ea0224206-6k_polypid.htm (6-K) — 12KB
- ea022420601ex99-1_polypid.htm (EX-99.1) — 10KB
- 0001213900-24-107630.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: December 11, 2024 By: /s/ Dikla Czaczkes Akselbrad Name: Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3